N-Boc-2-(4'-Chlorophenyl)-L-glycine, 95.0%, 250mg

3,6-Dibromothieno[3,2-b]thiophene>98.0%(GC)200mg

ethyl (2Z)-2-chloro-2-[2-(3,5-dimethylphenyl)hydrazin-1-ylidene]acetate, 95.0%, 5g

2-((2-((tert-Butoxycarbonyl)amino)ethyl)amino)acetic acid, 95+%, 5g

Solution étalon ICP baryum, 500mL, 1 000mg/L Ba, HDPE

Hyaluronic Acid 2-(2-Methyl-1-oxo-2-propen-1-yl)hydrazide (degree of substitution 20%)1g

2-(2-Bromopyridin-4-yl)acetic acid, 95.0%, 10g

4-(Trifluoromethylthio)bromobenzene, 97.0%, 10g

1,1'-(5'-(4-(1H-Imidazol-1-yl)phenyl)-[1,1':3',1''-terphenyl]-4,4''-diyl)bis(1H-imidazole), 97%, 10g

3-Methyl-6-nitrocoumarin, 95.0%, 1g

TOSEDOSTAT, 95%, 100mg

1-(2-Methoxy-phenyl)-pyrimidine-2,4,6-trione, 95.0%, 1g

BSTFA-TMCS (99:1) [Derivatizing Reagent for GC]25mL